View Future GrowthAtmofizer Technologies 과거 순이익 실적과거 기준 점검 0/6Atmofizer Technologies은 연평균 6.5%의 비율로 수입이 증가해 온 반면, Machinery 산업은 연평균 8.4%의 비율로 증가했습니다. 매출은 연평균 22.8%의 비율로 감소했습니다.핵심 정보6.46%순이익 성장률36.13%주당순이익(EPS) 성장률Machinery 산업 성장률16.34%매출 성장률-22.78%자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.공시 • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.공시 • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.공시 • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).공시 • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.공시 • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Atmofizer Technologies가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CNSX:ATMO 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 24001030 Sep 24001030 Jun 24001031 Mar 240-11031 Dec 230-11030 Sep 230-132030 Jun 230-176031 Mar 230-2210031 Dec 220-2816030 Sep 221-3221030 Jun 221-2919131 Mar 221-2616131 Dec 210-2112130 Sep 210-76130 Jun 210-54131 Mar 210-33031 Dec 200-110양질의 수익: ATMO 은(는) 현재 수익성이 없습니다.이익 마진 증가: ATMO는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ATMO는 수익성이 없지만 지난 5년 동안 연평균 6.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ATMO의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ATMO은 수익성이 없어 지난 해 수익 성장률을 Machinery 업계(1.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ATMO의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/27 21:26종가2025/02/27 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Atmofizer Technologies Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Peter-Thilo HaslerSphene Capital GmbH
공시 • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.
Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.
공시 • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.
공시 • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.
공시 • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).
공시 • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.
Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.
공시 • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.